266 related articles for article (PubMed ID: 19124806)
1. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
Chakraborty S; Sun CL; Francisco L; Sabado M; Li L; Chang KL; Forman S; Bhatia S; Bhatia R
J Clin Oncol; 2009 Feb; 27(5):791-8. PubMed ID: 19124806
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
[TBL] [Abstract][Full Text] [Related]
3. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
Darrington DL; Vose JM; Anderson JR; Bierman PJ; Bishop MR; Chan WC; Morris ME; Reed EC; Sanger WG; Tarantolo SR
J Clin Oncol; 1994 Dec; 12(12):2527-34. PubMed ID: 7989926
[TBL] [Abstract][Full Text] [Related]
4. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
5. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
Krishnan A; Bhatia S; Slovak ML; Arber DA; Niland JC; Nademanee A; Fung H; Bhatia R; Kashyap A; Molina A; O'Donnell MR; Parker PA; Sniecinski I; Snyder DS; Spielberger R; Stein A; Forman SJ
Blood; 2000 Mar; 95(5):1588-93. PubMed ID: 10688812
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related myelodysplasia and acute myeloid leukemia.
Bhatia S
Semin Oncol; 2013 Dec; 40(6):666-75. PubMed ID: 24331189
[TBL] [Abstract][Full Text] [Related]
7. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Jang GD; Kim SW; Suh CW; Kim EK; Bahng HS; Jeong YH; Park IG; Kim WK; Kim SH; Suh EJ; Park CJ; Ji HS; Lee JS
J Korean Med Sci; 2002 Aug; 17(4):555-9. PubMed ID: 12172056
[TBL] [Abstract][Full Text] [Related]
8. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Pedersen-Bjergaard J; Pedersen M; Myhre J; Geisler C
Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
Sobecks RM; Le Beau MM; Anastasi J; Williams SF
Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
[TBL] [Abstract][Full Text] [Related]
10. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
11. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma.
Legare RD; Gribben JG; Maragh M; Hermanowski-Vosatka A; Roach S; Tantravahi R; Nadler LM; Gilliland DG
Am J Hematol; 1997 Sep; 56(1):45-51. PubMed ID: 9298868
[TBL] [Abstract][Full Text] [Related]
12. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.
Li L; Li M; Sun C; Francisco L; Chakraborty S; Sabado M; McDonald T; Gyorffy J; Chang K; Wang S; Fan W; Li J; Zhao LP; Radich J; Forman S; Bhatia S; Bhatia R
Cancer Cell; 2011 Nov; 20(5):591-605. PubMed ID: 22094254
[TBL] [Abstract][Full Text] [Related]
13. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS.
Fern L; Pallis M; Ian Carter G; Seedhouse C; Russell N; Byrne J
Br J Haematol; 2004 Jul; 126(1):63-71. PubMed ID: 15198733
[TBL] [Abstract][Full Text] [Related]
14. NMR-based metabolomic analysis of the molecular pathogenesis of therapy-related myelodysplasia/acute myeloid leukemia.
Cano KE; Li L; Bhatia S; Bhatia R; Forman SJ; Chen Y
J Proteome Res; 2011 Jun; 10(6):2873-81. PubMed ID: 21510650
[TBL] [Abstract][Full Text] [Related]
15. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
[TBL] [Abstract][Full Text] [Related]
16. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma.
Traweek ST; Slovak ML; Nademanee AP; Brynes RK; Niland JC; Forman SJ
Blood; 1994 Aug; 84(3):957-63. PubMed ID: 8043877
[TBL] [Abstract][Full Text] [Related]
17. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Radivoyevitch T; Dean RM; Shaw BE; Brazauskas R; Tecca HR; Molenaar RJ; Battiwalla M; Savani BN; Flowers MED; Cooke KR; Hamilton BK; Kalaycio M; Maciejewski JP; Ahmed I; Akpek G; Bajel A; Buchbinder D; Cahn JY; D'Souza A; Daly A; DeFilipp Z; Ganguly S; Hamadani M; Hayashi RJ; Hematti P; Inamoto Y; Khera N; Kindwall-Keller T; Landau H; Lazarus H; Majhail NS; Marks DI; Olsson RF; Seo S; Steinberg A; William BM; Wirk B; Yared JA; Aljurf M; Abidi MH; Allewelt H; Beitinjaneh A; Cook R; Cornell RF; Fay JW; Hale G; Chakrabarty JH; Jodele S; Kasow KA; Mahindra A; Malone AK; Popat U; Rizzo JD; Schouten HC; Warwick AB; Wood WA; Sekeres MA; Litzow MR; Gale RP; Hashmi SK
Leuk Res; 2018 Nov; 74():130-136. PubMed ID: 30055822
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes.
Lacoste S; Bhatia S; Chen Y; Bhatia R; O'Connor TR
PLoS One; 2017; 12(2):e0171473. PubMed ID: 28207808
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantation.
Lambertenghi Deliliers G; Annaloro C; Pozzoli E; Oriani A; Della Volpe A; Soligo D; Lambertenghi Deliliers D; Tagliaferri E; Bertolli V; Romitti L
Leuk Res; 1999 Mar; 23(3):291-7. PubMed ID: 10071084
[TBL] [Abstract][Full Text] [Related]
20. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A; Carlo-Stella C; Ruella M; Miceli R; Devizzi L; Locatelli SL; Giacomini A; Testi A; Buttiglieri S; Risso A; Mariani L; Di Nicola M; Passera R; Tarella C; Gianni AM
Cancer; 2011 Nov; 117(22):5074-84. PubMed ID: 21567384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
